Bank Of America Corp Cardiff Oncology, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 45,364 shares of CRDF stock, worth $113,863. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,364

Previous 53,888 15.82%

Holding current value

$113,863

Previous $119,000 1.68%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.05 - $2.77 $17,474 - $23,611	-8,524 Reduced 15.82%	45,364 $121,000
Q2 2024 Aug 14, 2024	SELL	$2.22 - $5.89 $24,058 - $63,829	-10,837 Reduced 16.74%	53,888 $119,000
Q1 2024 May 15, 2024	BUY	$1.46 - $5.91 $21,808 - $88,277	14,937 Added 30.0%	64,725 $345,000
Q2 2023 Aug 14, 2023	SELL	$1.37 - $1.95 $41,278 - $58,753	-30,130 Reduced 37.7%	49,788 $73,000
Q1 2023 May 12, 2023	BUY	$1.45 - $2.09 $68,580 - $98,850	47,297 Added 144.99%	79,918 $131,000
Q4 2022 Feb 10, 2023	SELL	$1.22 - $1.66 $51,542 - $70,131	-42,248 Reduced 56.43%	32,621 $45,000
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $38,447 - $80,140	-24,966 Reduced 25.01%	74,869 $115,000
Q2 2022 Aug 12, 2022	BUY	$1.17 - $2.61 $97,542 - $217,595	83,370 Added 506.35%	99,835 $219,000
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $58,033 - $199,404	-27,504 Reduced 62.55%	16,465 $41,000
Q4 2021 Feb 08, 2022	SELL	$5.18 - $7.24 $6,754 - $9,440	-1,304 Reduced 2.88%	43,969 $264,000
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $75,560 - $114,321	15,082 Added 49.96%	45,273 $301,000
Q2 2021 Sep 13, 2021	BUY	$6.65 - $10.04 $200,770 - $303,117	30,191 New	30,191 $200,000

Others Institutions Holding CRDF

# of Institutions

Shares Held

12.3M

Call Options Held

813K

Put Options Held

91.1K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $109M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Cardiff Oncology, Inc. Transaction History